目的：評估間質性膀胱炎病患長期治療滿結果意度的預後因子。材料與方法：80位經多種方式治療質性膀胱炎的病患被納入本研究，分析人口統計資料及使用各種方式治療間質性膀胱炎效果是否顯著的相關性。結果:本研究共計11位男性及69位女性，平均年齡44.4歲，平均追蹤期間為8年，症狀顯著改善的有11位 (13.7%)，症狀普通改善的有50位 (63.5%)，治療失敗的有19位 (23.8%)。平均膀胱內壓測量容量大於350毫升、使用口服戊聚糖多磺胺類藥物 (oral pentosan polysulphate) 及規律追蹤都與治療結果滿意度有顯著的相關性。慢性間質性膀胱炎病患比起早期間質性膀胱炎的病患在初次診斷時有較長症狀期、較小的最大膀胱內壓測量容量及麻醉下實行水囊擴張術較小的最大膀胱容量。然而，病患的年齡、性別及間質性膀胱炎的種類對於治療結果滿意度並無臨床上的預後價值。結論：間質性膀胱炎的治療結果相差甚大，本研究發現規則的治療與口服戊聚糖多磺胺類藥物是症狀改善的預後因子。

OBJECTIVE: To evaluate the predictive factors of long-term therapeutic outcome in patients with interstitial cystitis (IC).MATERIALS AND METHODS: Eighty patients with IC treated using various therapeutic modalities were included in the analysis. The correlation of demographic data and various treatments with therapeutic results was analyzed.RESULTS: The study group was comprised of 11 men and 69 women (aged 44.4 ± 12.7 years), and the median follow-up period was 8 (range, 1~17) years. Significant improvement result was reported by 11 (13.7%) patients, an improved result by 50 (63.5%), and a failed result by 19 (23.8%). Cystometric bladder capacity of ＞350 ml, treatment with oral pentosan polysulphate, and regular follow-up were significantly associated with satisfactory therapeutic outcomes. Patients with chronic IC had a significantly longer duration of symptoms at diagnosis, a smaller cystometric bladder capacity, and a smaller maximum bladder capacity during hydrodilatation compared with patients with early IC. However, neither these variables nor age, gender, or type of IC had any predictive value for therapeutic outcomes.CONCLUSIONS: Therapeutic outcomes for IC greatly vary. This study found that regular treatment and oral pentosan polysulphate were predictors of improved results.